News
Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback